Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis

Cancer Science

Volumn 102, Issue 5, 2011, Pages 1045-1051

  Sato, Atsuko ^a   Kudo, Chieko ^a,b   Yamakoshi, Hiroyuki ^c   Uehara, Yoshihiko ^d   Ohori, Hisatsugu ^a,b   Ishioka, Chikashi ^a,b   Iwabuchi, Yoshiharu ^c   Shibata, Hiroyuki ^e  

^a TOHOKU UNIVERSITY   (Japan)

^b University Hospital   (Japan)

^c Graduate School of Pharmaceutical Science   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e AKITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; CYCLOOXYGENASE 2; GO Y 030; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; IC 50; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER; THYROID CANCER; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENE DERIVATIVES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; HUMANS; I-KAPPA B KINASE; KETONES; NF-KAPPA B; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 79954860747     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01886.x     Document Type: Article

References (24)

1. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9: 2723-35.
2. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
3. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-34.
4. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000; 275: 32592-7.
5. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1: 661-71.
6. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003; 22: 1313-24.
7. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-8.
8. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99.
9. Jobin C, Morteau O, Han DS, Balfour Sartor R. Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998; 95: 537-43.
10. Zong WX, Edelstein LC, Chen C, Bash J, Gélinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-7.
11. Tang G, Minemoto Y, Dibling B et al. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414: 313-7.
12. Meng Z, Mitsutake N, Nakashima M et al. Dehydroxymethyl-epoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 2008; 149: 5357-65.
13. Arlt A, Gehrz A, Müerköster S et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-51.
14. Pacifico F, Leonardi A. NF-kappaB in solid tumors. Biochem Pharmacol 2006; 72: 1142-52.
15. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
16. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2007; 75: 787-809.
17. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995-5000.
18. Park MJ, Kim EH, Park IC et al. Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol 2002; 21: 379-83.
19. Radulovic S, Bjelogrlic SK. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007; 12 (Suppl 1): S151-62.
20. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-61.
21. Dhillon N, Aggarwal BB, Newman RA et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
22. Ohori H, Yamakoshi H, Tomizawa M et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5: 2563-71.
23. Shibata H, Yamakoshi H, Sato A et al. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 2009; 100: 956-60.
24. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-74.